patient population News
-
Aurinia Pharmaceuticals to Present at the 11th Annual Leerink Global Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that the company will deliver a corporate presentation at the 11th Annual Leerink Global Healthcare Conference (February 14-18, 2022). The presentation will take place virtually on Wednesday, February 16, 2022 at 8 am ET. Interested parties can register to listen to the presentation via the public link here or ...
-
Aurinia Pharmaceuticals to Present at Upcoming Investor Conferences
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (the “Company”) today announced that members of the executive management team will give corporate presentations at two upcoming investor conferences including: Cowen 42nd Annual Virtual Healthcare Conference corporate presentation on Wednesday, March 9, 2022 at 12:50 p.m. ET. Link here Oppenheimer’s 32nd Annual Healthcare ...
-
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, today announced that the Company’s Compensation Committee granted 11 new employees inducement stock options to purchase an aggregate of 93,200 common shares, at a per share exercise price of $11.38, the closing ...
-
SoundBite Medical Solutions Announces First Use of its Novel 0.014” Active Wire to Successfully Treat Calcified Below-The-Knee CTOs
Soundbite Medical Solutions Inc. (SBMS) announced today the first use of its novel Active Wire 0.014” platform in the successful treatment of patients suffering from critical limb ischemia (CLI) with heavily calcified below-the-knee (BTK) chronic total occlusions (CTO). The procedures were performed by Professor Marianne Brodmann, Head of the Clinical Division of Angiology, Department of ...
-
CoreMap Wins National Science Foundation Phase 1 SBIR Award
CoreMap, Inc. announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Science Foundation (NSF) to support development of its technology aimed at expanding treatment opportunities for patients with Atrial Fibrillation (AF). AF is the most common and complex cardiac arrythmia affecting 33 million patients globally where patients are at ...
By CoreMap Inc.
-
Kurin, Inc. announces results on Kurin efficacy from Oishei Children`s Hospital with zero blood culture
Kurin Inc., the inventor and manufacturer of 510(k)-cleared Kurin® blood culture collection sets, announced today that Oishei Children’s Hospital, a member of Kaleida Health, in Buffalo, NY, presented their findings on their use of Kurin at the recent Association for Professionals in Infection Control conference. This is the first study of Kurin, a passive low-volume blood culture ...
By Kurin, Inc.
-
Data from Eli Lilly’s COV-BARRIER trial shows baricitinib reduced deaths in hospitalised COVID-19 patients by 38%
The latest data published in Eli Lilly’s Phase 3 randomised, double-blind, placebo-controlled study (COV-BARRIER) shows the largest clinical effect reported to date for a reduction in mortality in the COVID-19 patient population. Early in the pandemic, BenevolentAI researchers identified Baricitinib as a potential treatment for COVID-19 and published the hypothesis in The Lancet ...
By Benevolent
-
Adagio Medical Announces First Patient Enrollment in its iCLAS U.S. IDE Clinical Trial Evaluating Ultra-Low Temperature Cryoablation for Persistent Atrial Fibrillation
Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial. The FDA approved study aims to evaluate the safety and efficacy of Adagio’s ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF). Data will be used to support a ...
-
BenevolentAI announces first patient dosed in its Atopic Dermatitis clinical trial
BenevolentAI, a leader in the application of AI and machine learning in drug discovery and development, announced dosing of the first patient in its randomised first-in-human clinical trial of BEN-2293, a molecule designed and developed by BenevolentAI to treat Atopic Dermatitis. London, 11 February 2020 - This significant milestone sees a best in class, novel multi-target drug developed ...
By Benevolent
-
HistoSonics Receives FDA “Breakthrough Device Designation” for Novel Sonic Beam Therapy
HistoSonics announced today that the U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for its new therapy platform. Histotripsy of the liver provides clinicians the first automated external beam therapy using acoustic energy to mechanically destroy and liquefy tissue in the liver without incisions, ionizing radiation or heat. “The ...
By HistoSonics
-
Sanofi completes Kiadis acquisition
Sanofi (Euronext: SAN and NYSE: SNY) and Kiadis (Euronext Amsterdam and Brussels: KDS) today jointly announce the successful completion of Sanofi’s acquisition of Kiadis, a clinical-stage biopharmaceutical company developing next generation ‘off-the-shelf’ NK cell-therapies. Kiadis’ proprietary platform is based on allogeneic or ‘off-the-shelf' NK-cells from a ...
-
New Publication on TIF 2.0 in Therapeutic Advances in Gastroenterology Provides a Roadmap as Surgeons and Gastroenterologists Partner to Use the Procedure to Achieve Optimal Outcomes for Patients with Gastroesophageal Reflux Disease (GERD)
Continued evolution of EndoGastric Solutions’ EsophyX technology and concomitant use of TIF 2.0 with hiatal hernia repair brings long-term GERD relief to a broader spectrum of patients REDMOND, Wash – June 17, 2020 – EndoGastric Solutions® today announced the publication of a new review article in Therapeutic Advances in Gastroenterology1 that describes the refinement of ...
-
IlluminOss Medical Receives FDA Clearance for Expanded Clinical Use for Pelvic, Clavicle and Small-Bone Fractures
IlluminOss Medical, a medical device company focused on minimally invasive orthopedic fracture repair, today announced that it has received expanded U.S. Food and Drug Administration (FDA 510k) clearance for its Photodynamic Bone Stabilization System for treatment of fractures of the pelvis, clavicle, and the small bones of the hands and feet: metacarpals, metatarsals, and phalanges. The ...
-
Imaging Driven Innovation
Learn more about recent advances and software tools to leverage medical imaging data in the product lifecycle. Are you new to working with medical imaging data as an engineer? First you should find out if you will have access to DICOM or an other 3D or 4D medical imaging data format. If so, the complete range of software solutions are potentially available to you. If not, it’s not the ...
By Echobio, LLC
-
CathWorks FFRangio System Receives Regulatory Approval in Japan
CathWorks today announced the approval of The CathWorks FFRangio™ System by the Japan’s Ministry of Health, Labour and Welfare (MHLW). The CathWorks FFRangio System is a non-invasive diagnostic technology that is used at the time of a routine angiography. The CathWorks FFRangio System transforms routine angiogram images into objective and comprehensive physiology information, ...
By CathWorks
-
NeuroSigma Announces That a Team Led by UCLA Researchers Receives NIH Grant to Conduct a Multicenter Trial of eTNS for Pediatric ADHD
NeuroSigma, Inc., a bioelectronic medical device company, today announced that a team at the University of California, Los Angeles (UCLA) led by Professor Sandra Loo received a National Institutes of Health (NIH) grant to conduct a double-blind randomized controlled trial of eTNS for pediatric attention-deficit/hyperactivity disorder (ADHD). The trial will enroll up to 225 children with moderate ...
-
Healx pledges $25,000 to AKU Society patient registry campaign
Patient registries play a critical role in the development of treatments for rare diseases – 95% of which are still without an approved therapy today. Knowledge limitations around rare conditions are a huge barrier to treatment development and are compounded by the fact that rare disease patient populations are often small and geographically dispersed. Registries collect information ...
By Healx Ltd.
-
AI promises a new future of drug discovery for rare diseases
Despite affecting over 400 million people around the globe, rare diseases have largely been overlooked by traditional drug discovery methods. This is because traditional model often prioritise disease areas where there is a greater understanding of the basic underlying biology and which, in turn, generally come from the larger patient populations associated with more common diseases. This is part ...
By Healx Ltd.
-
Circassia Announces Publication of Tudorza Phase IV ASCENT Study in the Journal of the American Medical Association
Oxford, UK – 8 May 2019: Circassia Pharmaceuticals plc (“Circassia” or “the Company”; LSE: CIR), a specialty pharmaceutical company focused on respiratory disease, today announces the full publication of the Tudorza® phase IV ASCENT study in the prestigious Journal of the American Medical Association*. The ASCENT study was conducted in patients with ...
-
Rapid Medical Enrolls the First Patient in the DISTALS Stroke Trial–Offering Treatment to New Ischemic Stroke Patient Population
Rapid Medical, a leading developer of advanced neurovascular devices, announced today the enrollment of the first patient in the DISTALS Study. The trial is the first-ever FDA investigational device exemption (IDE) trial to examine the safety and effectiveness of mechanical thrombectomy in distal stroke. “Enrolling the first patient in this landmark study is an important milestone for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you